State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
July 19 2021 - 10:30AM
Business Wire
Quidel offers innovative “testing-as-a-service”
solution to Delaware’s K-12 schools
Students and faculty can opt-in for testing
with Quidel’s rapid antigen tests
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading
provider of rapid diagnostic testing solutions, cellular-based
virology assays and molecular diagnostic systems, announced today
that it is entering a partnership with the State of Delaware
to implement a full-service, turn-key COVID-19 testing program to
support the reopening of K-12 schools in the fall through its new
service provider, Quidel Services, LLC.
Under Quidel’s full-service program, Quidel will be responsible
for staffing test locations, coordinating sample collection,
running the tests, and reporting results to the Delaware Division
of Public Health (DPH) and the participating schools and school
districts to provide asymptomatic COVID-19 screening. Students and
faculty that opt-in to the COVID-19 screening program will be
tested with Quidel’s rapid antigen tests.
DPH and Delaware’s Department of Education will launch the
initiative at five pilot schools for summer school enrollees.
Quidel can expand the program to all of the State’s K-12 schools
when classrooms fully reopen for the fall semester. Under the
optional program, parental permission is required for participating
students.
“There is no greater need or responsibility than the safe
reopening of our K-12 classrooms to all Delaware children –
especially our youngest learners and disadvantaged children who
need in-person instruction the most,” said Delaware Governor
John Carney. “Regular COVID-19 testing is an important part of
our comprehensive mitigation strategy to get all students back to
in-person learning while reassuring parents that we are committed
to keeping their children safe while at school.”
“From the start of the pandemic to today’s partnership with the
State of Delaware, our dual purpose has been to create diagnostic
technologies for the protection of human life, and to make them
widely available so families can return to the joys of living and
learning with greater peace of mind,” said Douglas Bryant,
president and CEO of Quidel Corporation. “Working with the
State of Delaware, Quidel is taking a truly market-leading step on
that journey by introducing a complete testing-as-a-service model
with a goal of detecting COVID-19 infections early and protect
children, their classmates, teachers and families from potential
spread. Every day that we shut coronavirus down will be a day that
we keep classrooms open.”
Dr. Richard Pescatore, DPH Chief Physician, said, “We are
committed to ensuring student, educator and staff safety as we
reopen schools and associated student activities. We will monitor
results from weekly school testing closely to identify trends and
provide schools with the best guidance possible based on that data.
The surest defenses against COVID-19 are vigilant screening and
surveillance. Our rapid antigen in-school testing program with
Quidel makes that possible.”
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View our story told by our people at www.quidel.com/ourstory
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws that involve material
risks, assumptions and uncertainties. Many possible events or
factors could affect our future results and performance, such that
our actual results and performance may differ materially from those
that may be described or implied in the forward-looking statements.
As such, no forward-looking statement can be guaranteed.
Differences in actual results and performance may arise as a result
of a number of factors including, without limitation: the impact
and duration of the COVID-19 global pandemic; competition from
other providers of diagnostic products; our ability to accurately
forecast demand for our products and products in development,
including in new market segments; our ability to develop new
technologies, products and markets and to commercialize new
products; our reliance on sales of our COVID-19 and influenza
diagnostic tests; our reliance on a limited number of key
distributors; quantity of our product in our distributors’
inventory or distribution channels; changes in the buying patterns
of our distributors; the financial soundness of our customers and
suppliers; lower than anticipated market penetration of our
products; third-party reimbursement policies and potential cost
constraints; our ability to meet demand for our products;
interruptions, delays or shortages in the supply of raw materials,
components and other products and services; failures in our
information technology and storage systems; our exposure to data
corruption, cyber-based attacks, security breaches and privacy
violations; international risks, including but not limited to,
economic, political and regulatory risks; continuing worldwide
political and social uncertainty; our development, acquisition and
protection of proprietary technology rights; intellectual property
risks, including but not limited to, infringement litigation; the
loss of Emergency Use Authorizations for our COVID-19 products and
failures or delays in receipt of reviews or regulatory approvals,
clearances or authorizations for new products or related to
currently-marketed products by the U.S. Food and Drug
Administration (the “FDA”) or other regulatory authorities or loss
of any previously received regulatory approvals, clearances or
authorizations or other adverse actions by regulatory authorities;
our contracts with government entities involve future funding,
compliance and possible sanctions risks; product defects; changes
in government policies and regulations and compliance risks related
thereto; our ability to manage our growth strategy and successfully
identify, acquire and integrate potential acquisition targets or
technologies and our ability to obtain financing; our acquisition
of Alere’s Triage® business presents certain risks to our business
and operations; the level of our deferred payment obligations; our
exposure to claims and litigation that could result in significant
expenses and could ultimately result in an unfavorable outcome for
us, including the ongoing litigation between us and Beckman
Coulter, Inc.; we may need to raise additional funds to finance our
future capital or operating needs; our debt, deferred and
contingent payment obligations; competition for and loss of
management and key personnel; business risks not covered by
insurance; changes in tax rates and exposure to additional tax
liabilities or assessments; and provisions in our charter documents
and Delaware law that might delay or impede stockholder actions
with respect to business combinations or similar transactions.
Forward-looking statements typically are identified by the use of
terms such as “may,” “will,” “should,” “might,” “expect,”
“anticipate,” “estimate,” “plan,” “intend,” “goal,” “project,”
“strategy,” “future,” and similar words, although some
forward-looking statements are expressed differently. The risks
described in reports and registration statements that we file with
the Securities and Exchange Commission from time to time, should be
carefully considered, including those discussed in Item 1A, “Risk
Factors” and elsewhere in our Annual Report on Form 10 K for the
year ended December 31, 2020 and in our subsequent Quarterly
Reports on Form 10 Q. You are cautioned not to place undue reliance
on these forward-looking statements, which reflect management’s
analysis only as of the date of this press release. Except as
required by law, we undertake no obligation to publicly release any
revision or update of these forward-looking statements, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210719005461/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024